Annals of Hematology

, Volume 65, Issue 1, pp 1–5

Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications

  • M. Hallek
  • L. Wanders
  • S. Strohmeyer
  • B. Emmerich
Review Article

Summary

Thymidine kinase (TK) is a cellular enzyme which is involved in a “salvage pathway” of DNA synthesis. It is activated in the G1/S phase of the cell cycle, and its activity has been shown to correlate with the proliferative activity of tumor cells. Additionally, certain viruses are able to induce cellular TK production and activity. Clinical studies have reported elevated serum TK levels in a variety of neoplasias. The majority of these studies concerned hematologic malignancies. TK seems to be a useful marker in non-Hodgkin's lymphoma, where it correlates with clinical staging and provides significant prognostic information on (progression-free) survival. Preliminary results in acute myeloid leukemia indicate that pretreatment serum TK values may predict the response to the first induction chemotherapy. Moreover, serum TK appears to have some clinical value in such solid tumors as prostate cancer, breast cancer, and small-cell lung cancer, whereas it is not a reliable marker of non-small-cell lung cancer and brain tumors.

Key words

Thymidine kinase Tumor marker Prognosis Non-Hodgkin's lymphoma Viral infection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Archimbaud E, Vigreux B, Tigaud J-D, Maupas J, Guyotat D, Viala J-J, Fiere D (1988) Serum thymidine kinase in acute non-lymphocytic leukemia. Leukemia 2: 245–246Google Scholar
  2. 2.
    Bello LJ (1974) Regulation of thymidine kinase synthesis in human cells. Exp Cell Res 89: 263–274Google Scholar
  3. 3.
    Bieniarz A, Kulaga H, Medearis AL, Nakamura R, Platt LD, Paul RH (1988) Prenatal detection of fetal thymidine kinase activity in maternal plasma: normal values and clinical application in postterm pregnancy. Am J Obstet Gynecol 158: 560–564Google Scholar
  4. 4.
    Correale M, Abbate I (1990) Thymidine kinase (TK) as a tumor marker in breast cancer. Tumor Biol 11: 76Google Scholar
  5. 5.
    Deuß U, Allolio B, Kaulen D, Winkelmann W, Arnold W, Pack I (1987) Serum-Thymidinkinase als Tumormarker beim Bronchialkarzinom: Stadienabhängigkeit und Verlaufskontrollen. Tumor Diagn Ther 8: 69–74Google Scholar
  6. 6.
    Doi S, Naito K, Yamada K (1990) Serum deoxythymidine kinase as a progressive marker of hematological malignancy. Nagoya J Med Sci 52: 19–26Google Scholar
  7. 7.
    Dou QP, Fridovich-Keil JL, Pardee AB (1991) Inducible proteins binding to the murine thymidine kinase promoter in late G1/S phase. Proc Natl Acad Sci USA 88: 1157–1161Google Scholar
  8. 8.
    Ellims PH (1981) Thymidine kinase isozymes in chronic lymphocytic leukemia. Br J Haematol 49: 479–481Google Scholar
  9. 9.
    Ellims PH, Hayman RJ, van der Weyden MB (1980) Plasma thymidine kinase in megaloblastic anaemia. Br J Haematol 44: 167–168Google Scholar
  10. 10.
    Ellims PH, Eng Gan T, Medley G, van der Weyden MB (1981) Prognostic relevance of thymidine kinase in adult non-Hodgkin's lymphoma. Blood 58: 926–930Google Scholar
  11. 11.
    Eriksson B, Hagberg H, Glimelius B, Sundström C, Gronowitz JS (1985) Serum thymidine kinase as a prognostic marker in Hodgkin's disease. Acta Radiol Oncol 24: 167–171Google Scholar
  12. 12.
    Fischbach W, Schwarz WC, Jany B (1989) Neuron-specific enolase and thymidine kinase as an aid to the diagnosis and treatment monitoring of small cell lung cancer. Cancer 63: 1143–1149Google Scholar
  13. 13.
    Gronowitz JS, Hagberg H, Källander CFR, Simonsson B (1980) Optimized assay for thymidine kinase and its application for the detection of antibodies against herpes simplex virus type 1- and 2-induced thymidine kinase. Infect Immun 29: 425–434Google Scholar
  14. 14.
    Gronowitz JS, Källander CFR, Jeansson S, Wallin J (1982) Rapid typing of herpes simplex virus based on immunological specificity of viral thymidine kinase and typing according to sensitivity to iododeoxyuridine. J Clin Microbiol 15: 366–371Google Scholar
  15. 15.
    Gronowitz JS, Hagberg H, Källander CFR, Simonsson B (1983) The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47: 487–495Google Scholar
  16. 16.
    Gronowitz JS, Källander CFR, Diderholm H, Hagberg H, Petterson U (1984) Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 33: 5–12Google Scholar
  17. 17.
    Gronowitz JS, Källander CFR, Hagberg H, Persson L (1984) Deoxythymidine kinase in cerebrospinal fluid: a new potential “marker” for brain tumours. Acta Neurochir 73: 1–12Google Scholar
  18. 18.
    Gronowitz JS, Larsson A, Källander CFR, Claesson K, Sköberg O, Lernestedt JO, Frödin L, Tufveson G (1986) Serum thymidine kinase in transplantation patients: its relation to cytomegalovirus activity, renal transplant rejection and its use for monitoring antiviral therapy. Ann Clin Res 18: 71–75Google Scholar
  19. 19.
    Gronowitz JS, Bergstrom R, Nou E, Pahlman S, Brodin O, Nilsson S, Kallander CF (1990) Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 66: 722–732Google Scholar
  20. 20.
    Hagberg H, Glimelius B, Gronowitz JS, Killander A, Källander CFR, Schröder T (1984) Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multi-variate analysis. Scand J Haematol 33: 59–67Google Scholar
  21. 21.
    Hagberg H, Gronowitz JS, Killander A, Källander CFR (1984) Serum thymidine kinase in vitamin B12 deficiency. Scand J Haematol 32: 41–45Google Scholar
  22. 22.
    Hagberg H, Gronowitz JS, Killander A, Källander CFR, Simonsson B, Sundström C, Öberg G (1984) Serum thymidine kinase in acute leukemia. Br J Cancer 49: 537–540Google Scholar
  23. 23.
    Hallek M, Emmerich B, Reichle A, Schick HD, Senekowitsch R, Reinberg A (1988) Observation of circadian variations of serum thymidine kinase levels in control and tumor patients. Annu Rev Chronopharmacol: 361–364Google Scholar
  24. 24.
    Hallek M, Emmerich B, Strohmeyer S, Busch R, Reichle A, Senekowitsch R (1988) Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors. Klin Wochenschr 66: 718–723Google Scholar
  25. 25.
    Hallek M, Schick HD, Busch R, Strohmeyer S, Wanders L, Emmerich B (1990) Serum thymidine kinase in low and intermediate grade non-Hodgkin's lymphoma. Folia Oncol 13: 87–91Google Scholar
  26. 26.
    Hallek M, Wanders L, Schick HD, Busch R, Senekowitsch R, Emmerich B, Rastetter J (1990) Factors predicting the risk of progression in low and intermediate grade non-Hodgkin's lymphoma (NHL): a multivariate analysis (abstr). Proc Am Soc Clin Oncol 9: 272Google Scholar
  27. 27.
    Källander CFR, Gronowitz JS, Torfason EG (1982) Human serum antibodies to varicella-zoster virus thymidine kinase. Infect Immun 36: 30–37Google Scholar
  28. 28.
    Källander CFR, Gronowitz JS, Olding-Stenkvist E (1983) Rapid diagnosis of varicella-zoster virus infection by detection of viral deoxythymidine kinase in serum and vesicle fluid. J Clin Microbiol 17: 280–287Google Scholar
  29. 29.
    Källander CFR, Simonsson B, Hagberg H, Gronowitz JS (1984) Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer 54: 2450–2455Google Scholar
  30. 30.
    Källander CFR, Simonsson B, Gronowitz JS, Nilsson K (1987) Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia. Eur J Haematol 38: 331–337Google Scholar
  31. 31.
    Källander CFR, Gronowitz JS, Olding-Stenkvist E (1989) Varicella zoster virus deoxythymidine kinase is present before the onset of varicella. Scand J Infect Dis 21: 255–257Google Scholar
  32. 32.
    Kit S (1979) Viral-associated and induced enzymes. Pharmacol Ther 4: 501–585Google Scholar
  33. 33.
    Kit S, Leung WC, Jorgensen GN, Trkula D, Dubbs DR (1973) Viral-induced thymidine kinase isozymes. Prog Med Virol 21: 13–34Google Scholar
  34. 34.
    Larson A, Frödin L, Tufveson G, Larsson E, Källander CFR, Gronowitz JS (1986) Deoxythymidine kinase, a possible marker for monitoring activity of cytomegalovirus infection after renal transplantation. Scand J Urol Nephrol 20: 75–76Google Scholar
  35. 35.
    Lehtinen M, Wigren T, Lehtinen T, Kallioniemi OP, Aine R, Aaran RK, Ojala A (1988) Correlation between serum tumor marker levels and tumor proliferation in small cell lung cancer. Tumour Biol 9: 287–292Google Scholar
  36. 36.
    Lewenhaupt A, Ekman P, Eneroth P, Nilsson B (1990) Tumour markers as prognostic aids in prostatic carcinoma. Br J Urol 66: 182–187Google Scholar
  37. 37.
    Littler E, Baylis SA, Zeng Y, Conway MJ, Mackett M, Arrand JR (1991) Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet 337: 685–689Google Scholar
  38. 38.
    Luoni R, Ucci G, Riccardi A, Gobbi P, Avato FM, Vignale C, Ascari E (1992) Serum thymidine kinase in monoclonal gammopathies: a prospective study. Cancer 69: 1368–1372Google Scholar
  39. 39.
    McGuirt PV, Keller PM, Elion GB (1982) A radioimmunoassay for herpes simplex virus (HSV) thymidine kinase. Virology 116: 489–498Google Scholar
  40. 40.
    McKenna PG, O-Neill KL, Abram WP, Hannigan BM (1988) Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients. Br J Cancer 57: 619–622Google Scholar
  41. 41.
    Martinsson U, Glimelius B, Hagberg H, Sundstrom C (1988) Prognostic relevance of serum-markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas. Eur J Haematol 40: 289–298Google Scholar
  42. 42.
    Martinsson U, Glimelius B, Hagberg H, Sundstrom C (1989) Primarily asymptomatic low-grade non-Hodgkin lymphomas: prediction of symptom-free survival and total survival. Eur J Haematol 43: 332–338Google Scholar
  43. 43.
    Morgan MAM, Cooper EH, Bailey CC, Gronowitz JS, Källander CFR (1985) Serum deoxythymidine kinase in acute lympho-blastic leukaemia in children. Tumor Diagn Ther 6: 155–158Google Scholar
  44. 44.
    Nowrousian MR, Nagel-Hiemke M, May D, Niederle N, Maschmeyer G, Schmidt CG (1989) Serum thymidine kinase (S-TK) in acute leukemias and chronic myeloproliferative diseases (abstr). Proc Annu Meet Am Assoc Cancer Res 30: A 913Google Scholar
  45. 45.
    Pardee AB (1989) G1 events and regulation of cell proliferation. Science 246: 603–608Google Scholar
  46. 46.
    Pedersen C, Ingeberg S (1987) Serum thymidine kinase in AIDS patients treated with zidovudine (letter). Lancet 2: 460Google Scholar
  47. 47.
    Pedersen C, Ingeberg S, Stubbe Teglbjaerg L (1989) Serum thymidine kinase — a marker of bone marrow toxicity during treatment with zidovudine. Aids 3: 743–746Google Scholar
  48. 48.
    Persson L, Gronowitz JS, Kallander CF (1986) Thymidine kinase in extracts of human brain tumours. Acta Neurochir (Wien) 80: 123–127Google Scholar
  49. 49.
    Piersanti F, Feltrin F, Chiapetta F, Santilli S (1989) Deoxythymidine kinase: a marker of brain damage? Preliminary observations and considerations. Biochimical Clinica del Sistema Nervoso, Fisiopatologia, Diagnostica, Morfologia, Vicenza, Italy, May 26–27Google Scholar
  50. 50.
    Reichard P, Estborn B (1951) Utilization of deoxyribosides in the synthesis of polynucleotides. J Biol Chem 188: 839–846Google Scholar
  51. 51.
    Robertson JF, O'Neill KL, Thomas MW, McKenna PG, Blamey RW (1990) Thymidine kinase in breast cancer. Br J Cancer 62: 663–667Google Scholar
  52. 52.
    Russo SA, Harris MB, Greengard O (1987) Lymphocyte thymidine kinase and treatment response in acute lymphocytic leukemia. Leuk Res 11: 149–154Google Scholar
  53. 53.
    Simonsson B, Källander CFR, Brenning G, Killander A, Åhre A, Gronowitz JS (1985) Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma. Br J Haematol 61: 215–224Google Scholar
  54. 54.
    Simonsson B, Källander CFR, Brenning G, Killander A, Gronowitz JS, Bergström R (1988) Biochemical markers in multiple myeloma: a multivariate analysis. Br J Haematol 69: 47–53Google Scholar
  55. 55.
    Ucci G, Riccardi A, Luoni R, Spriano P, Merlini G, Danova M, Cassano E, Molinari E, Ascari E (1987) Serum thymidine kinase and β2-microglobulin in monoclonal gammopathies. Tumori 73: 445–449Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • M. Hallek
    • 1
    • 2
  • L. Wanders
    • 2
  • S. Strohmeyer
    • 2
  • B. Emmerich
    • 2
  1. 1.Dana-Farber Cancer InstituteHarvard Medical SchoolBostonUSA
  2. 2.Medizinische Klinik, Klinikum InnenstadtUniversität MünchenMünchen 2Germany

Personalised recommendations